BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15368549)

  • 1. Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders.
    Occhipinti E; Correa H; Yu L; Craver R
    Pediatr Blood Cancer; 2005 Mar; 44(3):240-4. PubMed ID: 15368549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplastic syndromes: the pediatric point of view.
    Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F
    Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
    Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
    Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic and myeloproliferative disorders in children.
    Hasle H
    Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases.
    Hasle H; Niemeyer CM; Chessells JM; Baumann I; Bennett JM; Kerndrup G; Head DR
    Leukemia; 2003 Feb; 17(2):277-82. PubMed ID: 12592323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [What to improve in approach to diagnose and treat pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia in Poland?].
    Wójcik D; Pietras W; Ussowicz M; Chybicka A
    Przegl Lek; 2006; 63(1):29-30. PubMed ID: 16892896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
    Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
    Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: retrospective analysis of 21 cases.
    Chen YC; Chou JM; Letendre L; Li CY
    Am J Hematol; 2005 Aug; 79(4):329-31. PubMed ID: 16044436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic myelomonocytic leukemia: lost in classification?
    Bowen DT
    Hematol Oncol; 2005 Mar; 23(1):26-33. PubMed ID: 16149105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.
    Barnard DR; Alonzo TA; Gerbing RB; Lange B; Woods WG;
    Pediatr Blood Cancer; 2007 Jul; 49(1):17-22. PubMed ID: 16856158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative review of classification systems in myelodysplastic syndromes (MDS).
    Bennett JM
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification].
    Fukuhara T; Kakinoki Y
    Rinsho Byori; 2006 Mar; 54(3):243-9. PubMed ID: 16637572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.
    Schmitt-Graeff A; Thiele J; Zuk I; Kvasnicka HM
    Haematologica; 2002 Apr; 87(4):392-9. PubMed ID: 11940483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetic evidence of Y chromosome loss in male patients with hematological disorders.
    Zhang LJ; Shin ES; Yu ZX; Li SB
    Chin Med J (Engl); 2007 Nov; 120(22):2002-5. PubMed ID: 18067786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.
    Phekoo KJ; Richards MA; Møller H; Schey SA;
    Haematologica; 2006 Oct; 91(10):1400-4. PubMed ID: 17018393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
    Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
    Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution.
    Breccia M; Latagliata R; Mengarelli A; Biondo F; Mandelli F; Alimena G
    Haematologica; 2004 Jul; 89(7):866-8. PubMed ID: 15257942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.